Gastroenterology Division, Department of Internal Medicine, University of Pennsylvania Health System, 1 Convention Avenue, 9 Penn Tower, Philadelphia, PA 19104, USA.
Surg Endosc. 2013 Aug;27(8):3039-42. doi: 10.1007/s00464-013-2813-y. Epub 2013 Feb 8.
Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) have transformed the ability to endoscopically remove superficial lesions throughout the gastrointestinal tract. The purpose of this study was to determine the properties and safety of a novel gel designed for the purpose of submucosal injection for EMR and ESD.
Upper endoscopy was performed in six Yorkshire pigs with 5-8 submucosal injections of varying amounts of Cook Medical (Bloomington, IN) gel were delivered in the stomach of each animal. A submucosal bleb of 1-2 ml normal saline was created followed by subsequent injection of 1-5 ml of the gel. Four animals were immediately euthanized and necropsy was performed after gel delivery and in two pigs; repeat endoscopy was performed after 4 weeks followed by necropsy.
Thirty-nine submucosal injections were performed in six pigs. Every injection resulted in adequate mucosal lifting with a shoulder and defined margin and no cases of gel extravasation. Twenty-seven injections were performed in four pigs followed by immediate necropsy. The submucosal cushion was still present at the time of organ extraction without evidence of perforation, bleeding or tissue damage. Unroofing of the mucosal layer demonstrated a clean submucosal tissue dissection without bleeding or tissue damage. Twelve submucosal injections were performed in two pigs, and repeat endoscopy at 4 weeks demonstrated persistent submucosal cushion without evidence of mucosal ischemia or ulceration. Necropsy demonstrated no evidence of perforation, bleeding, or gel extravasation. Unroofing the mucosa confirmed a clean submucosal dissection. The injectate did not result in mesenteric fibroinflammatory reaction, tissue damage, or adhesion formation after 4 weeks.
The gel appears to be a safe injectate that provides a submucosal cushion with a duration that is longer than other available injectates for EMR and ESD. The clean submucosal dissection may decrease the length of these procedures while minimizing complications.
内镜黏膜切除术(EMR)和内镜黏膜下剥离术(ESD)改变了内镜切除胃肠道浅表病变的能力。本研究旨在确定一种新型凝胶的特性和安全性,该凝胶专为 EMR 和 ESD 的黏膜下注射而设计。
对 6 只约克夏猪进行上消化道内镜检查,每只动物胃内注射 5-8 种不同剂量的库克医学(印第安纳州布鲁明顿)凝胶。先注入 1-2ml 生理盐水形成黏膜下隆起,然后注入 1-5ml 凝胶。4 只动物立即安乐死,在凝胶注射后进行尸检;另外 2 只猪在 4 周后重复内镜检查,然后进行尸检。
在 6 只猪中进行了 39 次黏膜下注射。每次注射均能充分抬高黏膜,形成肩状和明确的边缘,无凝胶外渗。在 4 只猪中进行了 27 次注射,随后立即进行尸检。在器官提取时,黏膜下垫仍存在,无穿孔、出血或组织损伤的证据。黏膜层的揭顶显示出无出血或组织损伤的干净的黏膜下组织剥离。在 2 只猪中进行了 12 次黏膜下注射,4 周后的重复内镜检查显示持续存在的黏膜下垫,无黏膜缺血或溃疡的证据。尸检未发现穿孔、出血或凝胶外渗。揭顶确认了干净的黏膜下剥离。4 周后,注射物未引起肠系膜纤维炎性反应、组织损伤或粘连形成。
该凝胶似乎是一种安全的注射剂,提供的黏膜下垫持续时间长于其他用于 EMR 和 ESD 的可注射剂。干净的黏膜下剥离可能会缩短这些手术的时间,同时最大限度地减少并发症。